Locations:
Search IconSearch

Bone Turnover Persists 5 Years Post-Bariatric Surgery in T2D Patients

There is a need for ongoing monitoring

Cleveland Clinic researchers from the Department of Endocrinology, Diabetes and Metabolism and the Bariatric and Metabolic Institute have been collaborating to minimize the progression of type 2 diabetes in obese patients for some time. Last year the group published five-year outcomes from the groundbreaking STAMPEDE study showing the benefit of bariatric surgery in these patients, including significant improvements in weight loss, glycemic control, triglyceride and HDL cholesterol levels, use of insulin, and quality of life.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Now, the group has just published findings from an ancillary analysis of the STAMPEDE data. This analysis shows that while the benefits are sustained five years post-surgery, these patients do have chronically elevated bone turnover markers, a sign that they are at increased risk for fractures.

“Our study validates the findings of others, namely that these patients face increased risk for both osteoporosis and fractures,” says Sangeeta Kashyap, MD, from the Department of Endocrinology, who was an author on both studies. “While this may be a drawback, we have to weigh the risk of potential fractures against the benefits of improved glycemic control achieved by these surgeries.

What the study found

The ancillary study sought to measure the five-year outcomes of bariatric surgery versus guideline-recommended intensive medical therapy on bone turnover in 95 obese patients (median BMI: 36.5; range 27-43) with uncontrolled type 2 diabetes (median HbA1c: 9.3). Patients had been randomized in the STAMPEDE trial to intensive medical therapy (IMT; n = 25), Roux-en-Y gastric bypass (RYGB; n = 37), or sleeve gastrectomy (SG: n=33) for diabetes treatment. Osteocalcin (OC, a bone formation marker), serum C-telopeptide of type 1 collagen (CTX, a bone resorption marker), and intact parathyroid hormone (PTH) were assessed at baseline and five years post-surgery. (For more on the STAMPEDE trial, visit here.)

At five years, both surgical groups had noticeably significant percent increases in CTX and OC compared to the IMT group (see table). The decrease in BMI was related to increase in CTX for all 95 patients. While the surgical groups also had significant increases in PTH, the IMT group did not. However, the authors note that PTH values did not differ significantly among the groups at five years.

Advertisement

Baseline and 5-year data for bone turnover markers

Intensive Medical Therapy (n =25)
Baseline
Roux-en-Y Bypass (n =37)
5 years
Sleeve Gastrectomy (n =33)
Baseline
5 years
Baseline
5 years
Serum C-telopeptide of type 1 collagen (CTX, ng/mL)
Roux-en-Y Bypass (n =37)
0.27±0.11
Sleeve Gastrectomy (n =33)
0.31±0.18
0.22±0.10
0.49±0.25
0.25±0.14
0.36±0.20
Percent change
Roux-en-Y Bypass (n =37)
29.8±92% (p=0.12)
Sleeve Gastrectomy (n =33)
137±108% (p<0.001)
61.1±90% (p<0.001)
Osteocalcin (OC, ng/mL)
Roux-en-Y Bypass (n =37)
11.2±3.8
Sleeve Gastrectomy (n =33)
14.3±8.8
9.6±3.1
23.3±11.8
10.9±4.1
17.4±6.8
Percent change
Roux-en-Y Bypass (n =37)
43.8±121.1% (p<0.83)
Sleeve Gastrectomy (n =33)
138.9±19% (p<0.001)
71±69% (p<0.001)
Parathyroid hormone (PTH, pg/mL)
Roux-en-Y Bypass (n =37)
42.6±14.7
Sleeve Gastrectomy (n =33)
44.14.6
39.6±17.1
56.5±24.4
44.4±25.8
50.7±23.8
Percent changed
Roux-en-Y Bypass (n =37)
Not reported

Twelve patients reported 13 fractures during the 5-year period, including 11 in the feet/ankles and two in the distal arm/hand.

While these data demonstrate a correlation of increased bone turnover after weight loss, not a causative relationship, Dr. Kashyap notes they do show that patients who undergo bariatric surgery will need on-going monitoring for increased bone turnover.

Advertisement

Related Articles

Ablation surgery image
Efficacy of RFA for Symptomatic Thyroid Nodules Validated by Objective Questionnaire

Radiofrequency ablation significantly reduces symptom severity, shrinks nodules

Diabetes and pregnancy
November 8, 2023/Diabetes & Endocrinology
New Programs Support the Needs of Patients with Pregnancy and Diabetes

Maternal-fetal medicine specialists, endocrinologists and educators team up

Patient counseling
Transitioning from Pediatric to Adult Care for Obesity

Giving young patients a hand as they take charge of their own health

Pregnant woman on couch
When Hypertension in Pregnancy Signals Something Else

Case illustrates how easily condition can mimic preeclampsia

giant prolactinoma
Surgical Management of Giant Prolactinomas

Analysis examines surgical resection of rare pituitary tumors

chronic kidney disease
Improving Management of Diabetes and Chronic Kidney Disease

Screening and medication key to better outcomes

diabetic neuropathy
August 30, 2023/Diabetes & Endocrinology
Significant Relief for Some With Diabetic Neuropathy

Spinal cord stimulation can help those who are optimized for success

Endocrinopathies
Endocrinopathies from Checkpoint Inhibitors

Incidence, outcomes and management

Ad